A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth

Pancreatic cancer is one of the most lethal human diseases, with an all-stage 5-year survival rate below 5%. To date, no effective and specific therapy is available for this disease. Mutations in KRAS are frequently reported in pancreatic and many other cancers; thus, KRAS is an attractive therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Ting, Zhang, Yiwen, Zhou, Nan, He, Xin, Chen, Cancan, Liang, Liting, Duan, Xiaobing, Lin, Yingtong, Wu, Kang, Zhang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190097/
https://www.ncbi.nlm.nih.gov/pubmed/27322423
http://dx.doi.org/10.18632/oncotarget.9996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190097/
https://www.ncbi.nlm.nih.gov/pubmed/27322423
http://dx.doi.org/10.18632/oncotarget.9996

Ejemplares similares